A review of postmarket safety studies by the US Food and Drug Administration (FDA) has found no significant increase in risk for serious asthma-related outcomes when a long-acting β-agonist (LABA) is ...

CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...

• MOA: airway muscarinic acetylcholine receptor antagonist • Superior to doubling dose of ICS; non-inferior to ICS+ LABA therapy in African American patients with uncontrolled asthma • Increases time ...

The four trials also assessed efficacy of the ICS/LABA products. Based on a review of four clinical safety trials, the Food and Drug Administration (FDA) has concluded that medications that contain ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved updates to the SYMBICORT ® (budesonide ...

LABA/LAMA is associated with a similar or lower risk of cardiovascular and cerebrovascular adverse events compared to treatment with LABA/inhaled corticosteroid. According to a new study published in ...

Triple therapy for COPD, vs ICS/LABA therapy, was independently associated with ischemic heart disease, heart failure, arrhythmia, and atrial fibrillation/flutter. Cardiovascular events in patients ...